Posters

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated Apolipoprotein E-deficient mice

      Stolle, K.; Berges, A.; Lietz, M.; Lebrun, S.; Schleef, R.; Wallerath, T.

      Conference date
      Feb 24, 2009
      Conference name
      Keystone Symposia - Dissecting the Vasculature: Function, Molecular Mechanisms, and Malfunction
      Link to more information
      Topic
      Summary

      Epidemiologic research has shown a correlation between cigarette smoke and the risk of developing atherosclerosis and associated pathological processes including abdominal aortic aneurysms (AAA). Hyperlipidemia and hypertension are additional risk factors for atherosclerosis. The hyperlipideamic apolipoprotein e-knockout (ApoE-/-) mouse is a well-established animal model system for studying the mechanisms of the atherosclerotic process. In this study, we examined the mechanistic effects occurring as three risk factors interact in the atherosclerotic process. Hypertension was induced in hyperlipidemic apolipoprotein-e-knockout (ApoE-/-) mice by application of angiotensin-II and the mice were exposed to mainstream smoke from the reference cigarette 2R4F (University of Kentucky) for 30 days. AAA formation was seen only in angiotensin-ii treated ApoE-/--mice. The incidence and severity of AAA were further increased by smoke exposure. Expression of matrix metalloproteinases-(MMP)-2, -3, -8, -9, and -12 in AAA was enhanced in smoke-exposed angiotensin-II treated hyperlipemic mice. Zymographic activity analysis revealed that the activity of MMP-9 and MMP-2 was highest in the mice exposed to all three risk factors. This study showed for the first time that formation and severity of AAA in hypertensive and hyperlipidemic ApoE-/- mice are accelerated by exposure to cigarette mainstream smoke, suggesting that this animal model may be suitable for studying mechanisms of AAA development.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.